| Literature DB >> 28719954 |
Arpa Surapaitoon1,2, Sutas Suttiprapa2,3, Eimorn Mairiang4, Narong Khuntikeo5, Chawalit Pairojkul3, Jeffrey Bethony6, Paul J Brindley6, Banchob Sripa2,3.
Abstract
Opisthorchis viverrini infection induces chronic inflammation, and a minor proportion of infected individuals develop advanced periductal fibrosis (APF) and cholangiocarcinoma (CCA). Inflammatory cytokines and/or their gene polymorphisms may link to these biliary pathologies. We therefore investigated associations among cytokine gene polymorphisms and cytokine production in 510 Thai cases infected with O. viverrini who presented with APF+ or APF-, as established by abdominal ultrasonography as well as in patients diagnosed with CCA. Levels of pro-inflammatory and anti-inflammatory cytokines were determined in culture supernatants after stimulation of peripheral blood mononuclear cells (PBMCs) with O. viverrini excretory-secretory (ES) products. Pro-inflammatory cytokines, IL-1β, IL-6, IFN-γ, LT-α, and TNF-α were significantly increased in CCA patients compared with non-CCA (APF- and APF+) cases. Polymorphisms in genes encoding IL-1β-511C/T, IL-6-174G/C, IFN-γ +874T/A, LT-α +252A/G, and TNF-α -308G/A were then investigated by using PCR-RFLP or allele specific-PCR (AS-PCR) analyses. In the CCA cases, LT-α +252A/G and TNF-α -308G/A heterozygous and homozygous variants showed significantly higher levels of these cytokines than the wild type. By contrast, levels of cytokines in wild type of IFN-γ +874T/A were significantly higher than the variants in CCA cases. IFN-γ +874T/A polymorphisms were associated with advanced periductal fibrosis, whereas IL-6 -174G/C polymorphisms were associated with CCA. To our knowledge, these findings provide the first demonstration that O. viverrini infected individuals carrying several specific cytokine gene polymorphisms are susceptible to develop fibrosis and CCA.Entities:
Keywords: Opisthorchis viverrini; advanced periductal fibrosis; cholangiocarcinoma; cytokine gene polymorphisms; hepatobiliary disease
Mesh:
Substances:
Year: 2017 PMID: 28719954 PMCID: PMC5523895 DOI: 10.3347/kjp.2017.55.3.295
Source DB: PubMed Journal: Korean J Parasitol ISSN: 0023-4001 Impact factor: 1.341
Primer sequences, restriction enzymes, and size of digestion products in the PCR-RFLP and AS-PCR analyses
| Gene/SNP | rsn | wt/var | Region | Oligonucleotide primers | RE | Digestion products (bp) |
|---|---|---|---|---|---|---|
| IL-1β/−511 | rs16944 | C/T | Promoter | F (5′-TGG CAT TGA TCT GGT TCA TC-3′) | wt: 190, 114 | |
| IL-6/−174 | rs1800795 | G/C | Promoter | F (5′-GGG CTG CGA TGG AGT CGA AG-3′) | wt: 233, 54 | |
| IFN-γ/+874 | rs2430561 | T/A | Intron 1 | Common primer: 5′TCAACAAAGCTGATACTCCA-3′, T allele primer: 5′TTCTTACAACACAAAATCAAATCT-3′, A allele primer: 5′TCTTACAACACAAAATCAAATCA-3′ | ||
| LT-α/+252 | rs909253 | A/G | intron | F (5′-CCG TGC TTC GTG CTT TGG ACT A-3′) | wt: 427 | |
| TNF-α/−308 | rs1800629 | G/A | promoter | F (5′-TCC TCC CTG CTC CGA TTA CG-3′) | wt: 87 |
SNP, Single nucleotide polymorphism; rsn, reference SNP number; wt, wild type; var, variant; RE, restriction enzyme; bp, base pair
Fig. 1Representative amplicons and digestion fragments corresponding to gene polymorphisms. (A) 190 and 114 bp fragments specific for C allele, 304 bp fragment specific for T allele of IL-1b-511C/T polymorphism. (B) 233 bp and 54 bp bands specific for G allele, 122 bp, 111 bp, and 54 bp bands specific for C allele of IL-6-174G/C polymorphism. C) 262 bp fragment specific for T and A alleles of IFN-γ +874T/A polymorphism. (D) 427 bp fragment specific for A allele, 231 and 196 bp fragments specific for G allele of LT-α +252A/G polymorphism. (E) 107 bp fragment specific for A allele, 87 bp fragments specific for G allele of TNF-α −308G/A polymorphism. M, 50 bp DNA marker.
Clinicopathological characteristics of cholangiocarcinoma (CCA) patients and non-CCA controls
| Demographics | APF− (n=200) | APF+ (n=200) | CCA (n=110) |
|---|---|---|---|
| Sex | |||
| Male (%) | 91 (45.5) | 92 (46.0) | 72 (65.5) |
| Female (%) | 109 (54.5) | 108 (54.0) | 38 (34.5) |
|
| |||
| Age (years) | |||
| Mean±SD | 46.8 ±7.7 | 47.4±7.5 | 55.9±10.3 |
| Range | 20–60 | 22–60 | 40–76 |
|
| |||
| Age (in year; %) | |||
| ≤ 30 | 6 (3.0) | 5 (2.5) | 1 (0.9) |
| 31–40 | 34 (17.0) | 33 (16.5) | 5 (4.6) |
| 41–50 | 86 (43.0) | 83 (41.5) | 20 (18.2) |
| ≥ 51 | 74 (37.0) | 79 (39.5) | 84 (46.4) |
Fig. 2Net cytokine profile of OvES stimulated PBMCs in APF−, APF+, and CCA patients. The Wilcoxon Matched-paired Signed rank test was used to assess the statistical significance; *P<0.05.
Fig. 3The net production of IL-1β, IL-6, IFN-γ, LT-α, and TNF-α, and their genotype polymorphisms in APF− (n=200), APF+ (n=200), and CCA patients (n=110). wt, wild type; hetero, heterozygous; var, variant.
Comparison of genotypes and allele frequencies for IL-1β, IL-6, IFN-γ, LT-α, and TNF-α in CCA cases and the participants in the APF+ and the APF− groups
| Cytokine/Genotype/Allele | APF−N(%) | APF+N(%) | CCA N(%) | APF− vs. APF+ | APF− vs. CCA | APF+ vs. CCA |
|---|---|---|---|---|---|---|
|
| ||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| IL-1β (−511C/T) | ||||||
| CC | 38 (19.0) | 36 (18.0) | 18 (16.1) | 1 | 1 | 1 |
| CT | 100 (50.0) | 93 (46.5) | 48 (43.6) | 0.98 (0.50–1.74) | 1.01 (0.50–2.09) | 1.03 (0.50–2.14) |
| TT | 62 (31.0) | 71 (35.5) | 44 (40.0) | 1.20 (0.65–2.22) | 1.49 (0.72–3.16) | 1.23 (0.59–2.61) |
| C | 176 (44.0) | 165 (41.2) | 84 (38.2) | 1 | 1 | 1 |
| T | 244 (56.0) | 235 (58.8) | 136 (61.8) | 1.02 (0.77–1.36) | 1.16 (0.82–1.65) | 1.13 (0.80–1.61) |
|
| ||||||
| IL-6 (−174G/C) | ||||||
| GG | 112 (56.0) | 124 (62.0) | 32 (29.1) | 1 | 1 | 1 |
| GC | 67 (33.5) | 59 (29.5) | 45 (40.9) | 0.79 (0.50–1.25) | 2.35 (1.31–4.21) | 2.95 (1.64–5.31) |
| CC | 21 (10.5) | 17 (8.5) | 33 (30.0) | 0.73 (0.34–1.53) | 5.50 (2.65–11.41) | 7.52 (3.52–16.19) |
| G | 291 (72.7) | 307 (76.7) | 109 (49.5) | 1 | 1 | 1 |
| C | 109 (27.3) | 93 (23.3) | 111 (50.5) | 0.81(0.58–1.13) | 0.26 (0.12–0.52) | 3.36 (2.32–4.85) |
|
| ||||||
| IFN-γ (+874T/A) | ||||||
| TT | 61 (30.5) | 26 (13.0) | 23 (20.9) | 1 | 1 | 1 |
| TA | 74 (37.0) | 98 (49.0) | 33 (30.0) | 3.10 (1.73–5.61) | 1.18 (0.60–2.34) | 0.38 (0.18–0.80) |
| AA | 65 (32.5) | 76 (38.0) | 54 (49.1) | 2.74 (1.50–5.04) | 2.20 (1.13–4.20) | 0.80 (0.39–1.64) |
| T | 196 (49.0) | 150 (37.5) | 79 (35.9) | 1 | 1 | 1 |
| A | 204 (51.0) | 250 (62.5) | 141 (64.1) | 1.60 (1.19–2.14) | 1.71 (1.20–2.44) | 1.07 (0.75–1.5) |
|
| ||||||
| LT-α (+252A/G) | ||||||
| AA | 60 (30.0) | 47 (23.5) | 24 (21.8) | 1 | 1 | 1 |
| AG | 74 (37.0) | 93 (46.5) | 54 (49.1) | 1.60 (0.95–2.65) | 1.84 (0.97–3.45) | 1.17 (0.60–2.16) |
| GG | 66 (33.0) | 60 (30.0) | 32 (29.1) | 1.16 (0.66–2.01) | 1.21 (0.61–2.40) | 1.04 (0.51–2.11) |
| A | 194 (48.5) | 187 (46.8) | 102 (46.4) | 1 | 1 | 1 |
| G | 206 (51.5) | 213 (53.2) | 118 (53.6) | 1.07 (0.80–1.43) | 1.08 (0.77–1.53) | 1.01 (0.72–1.43) |
|
| ||||||
| TNF-α (−308G/A) | ||||||
| GG | 34 (17.0) | 35 (17.5) | 17 (15.5) | 1 | 1 | 1 |
| GA | 54 (27.0) | 46 (23.0) | 13 (11.8) | 0.82 (0.42–1.60) | 0.48 (0.18–1.20) | 0.58 (0.22–1.47) |
| AA | 112 (56.0) | 119 (59.5) | 80 (72.7) | 1.03 (0.58–1.83) | 1.42 (0.71–2.92) | 1.38 (0.69–2.82) |
| G | 122 (30.5) | 116 (29.0) | 47 (21.4) | 1 | 1 | 1 |
| A | 278 (69.5) | 284 (71.0) | 173 (78.6) | 1.07 (0.78–1.47) | 1.61 (1.08–2.43) | 1.50 (1.00–2.26) |
Significant at P-value<0.05.
Cytokine levels as established in PBMCs pulsed with excretory secretory profcuts of the liver fluke Opisthorchis viverrini and the net cytokine production and genotype polymorphisms
| Cytokine levels, pg/ml | |||
|---|---|---|---|
| Wild type | Heterozygous | Variant | |
| IL-1β | 268.4±47.7 | 315.4±35.9 | 303.1±41.1 |
| IL-6 | 3,973.1±763.2 | 4,221.6±434.8 | 4,323.7±440.5 |
| IFN-γ | 514.9±140.3 | 397.5±117.4 | 239.9±65.2 |
| LT-α | 67.3±17.9 | 187.4±36.0 | 153.7±36.7 |
| TNF-α | 362.6±68.8 | 498.8±127.1 | 466.7±67.9 |
Cytokine levels presented as mean±SD;
P<0.05; n=510.